{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:56:44Z","timestamp":1763017004396,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2010,2,15]],"date-time":"2010-02-15T00:00:00Z","timestamp":1266192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,2,15]],"date-time":"2010-02-15T00:00:00Z","timestamp":1266192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1038\/bmt.2010.25","type":"journal-article","created":{"date-parts":[[2010,2,15]],"date-time":"2010-02-15T11:52:34Z","timestamp":1266234754000},"page":"1625-1630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma"],"prefix":"10.1038","volume":"45","author":[{"given":"D","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Loh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H J","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Chuah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G C","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y C","family":"Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L C","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S L","family":"Tien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L H","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y T","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,15]]},"reference":[{"key":"BFbmt201025_CR1","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.","journal-title":"N Engl J Med"},{"key":"BFbmt201025_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021\u20131030.","journal-title":"N Engl J Med"},{"key":"BFbmt201025_CR3","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1200\/JCO.2009.22.7389","volume":"27","author":"M Cavo","year":"2009","unstructured":"Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF et al. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. J Clin Oncol 2009; 27: 5001\u20135007.","journal-title":"J Clin Oncol"},{"key":"BFbmt201025_CR4","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BFbmt201025_CR5","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1365-2141.2000.02012.x","volume":"109","author":"JJ Lahuerta","year":"2000","unstructured":"Lahuerta JJ, Martinez-Lopez J, Serna JD, Blad\u00e9 J, Grande C, Alegre A et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438\u2013446.","journal-title":"Br J Haematol"},{"key":"BFbmt201025_CR6","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3324\/haematol.11534","volume":"92","author":"H Van de Velde","year":"2007","unstructured":"Van de Velde H, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M . Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399\u20131406.","journal-title":"Haematologica"},{"key":"BFbmt201025_CR7","unstructured":"Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M et al. CR represents an early index of potential long survival in multiple myeloma. 2009; (e-pub ahead of print 27 July 2009) PMID: 19633690."},{"key":"BFbmt201025_CR8","doi-asserted-by":"crossref","unstructured":"Harousseau J-L, Attal M, Moreau P, Garban F, Facon T, Avet-Loiseau H . The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double transplantation program for newly diagnosed multiple myeloma (MM): combined results of the IFM 99 trials. Blood 2006; 108 (Abstract 3077).","DOI":"10.1182\/blood.V108.11.3077.3077"},{"key":"BFbmt201025_CR9","doi-asserted-by":"publisher","first-page":"7037","DOI":"10.1158\/1078-0432.CCR-07-0527","volume":"13","author":"J Haessler","year":"2007","unstructured":"Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van Rhee F et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7037\u20137079.","journal-title":"Clin Cancer Res"},{"key":"BFbmt201025_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cncr.23546","volume":"113","author":"B Barlogie","year":"2008","unstructured":"Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008; 113: 355\u2013359.","journal-title":"Cancer"},{"key":"BFbmt201025_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1634\/theoncologist.12-6-664","volume":"12","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Mitsiadis C, Schlossman R, Munshi N, Anderson K . New drugs for myeloma. Oncologist 2007; 12: 664\u2013689.","journal-title":"Oncologist"},{"key":"BFbmt201025_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3816\/CLM.2007.s.024","volume":"5","author":"S Jagannath","year":"2007","unstructured":"Jagannath S . Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma 2007; 5: 207\u2013214.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFbmt201025_CR13","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle RA, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962\u20132972.","journal-title":"Blood"},{"issue":"15_suppl","key":"BFbmt201025_CR14","doi-asserted-by":"publisher","first-page":"8505","DOI":"10.1200\/jco.2008.26.15_suppl.8505","volume":"26","author":"J. L. Harousseau","year":"2008","unstructured":"Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Hullin C et al. Bortezomib\/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005\/01 trial. J Clin Oncol 2008; 26 (Abstract 8505).","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"BFbmt201025_CR15","doi-asserted-by":"publisher","first-page":"8521","DOI":"10.1200\/jco.2008.26.15_suppl.8521","volume":"26","author":"J. A. Zonder","year":"2008","unstructured":"Zonder JA, Crowley JJ, Bolejack V, Hussein M, Morre DF, Whittenberger BF et al. A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results. J Clin Oncol 2008; 26 (Abstract 8521).","journal-title":"Journal of Clinical Oncology"},{"key":"BFbmt201025_CR16","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1200\/JCO.2008.21.1060","volume":"27","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 trials. J Clin Oncol 2009; 27: 5720\u20135726.","journal-title":"J Clin Oncol"},{"key":"BFbmt201025_CR17","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR . Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431\u2013436.","journal-title":"J Clin Oncol"},{"key":"BFbmt201025_CR18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825\u2013831.","journal-title":"Lancet"},{"key":"BFbmt201025_CR19","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2006-04-019778","volume":"108","author":"MV Mateos","year":"2006","unstructured":"Mateos MV, Hernandez JM, Hernandez MT, Gutierrez NC, Palomera L, Fuertes M et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1\/2 study. Blood 2006; 108: 2165\u20132172.","journal-title":"Blood"},{"key":"BFbmt201025_CR20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906\u2013917.","journal-title":"N Engl J Med"},{"key":"BFbmt201025_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"P Moreau","year":"2002","unstructured":"Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F et al. Comparison of 200\u2009mg\/m(2) melphalan and 8 Gy total body irradiation plus 140\u2009mg\/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002; 99: 731\u2013735.","journal-title":"Blood"},{"key":"BFbmt201025_CR22","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, San Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFbmt201025_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. Am Stat assoc 1958; 53: 457\u2013484.","journal-title":"Am Stat assoc"},{"key":"BFbmt201025_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2307\/2529177","volume":"29","author":"R Peto","year":"1973","unstructured":"Peto R, Pike MC . Conservatism of the approximation sigma (O-E)2-E in the log rank test for survival data or tumor incidence data. Biometrics 1973; 29: 579\u2013584.","journal-title":"Biometrics"},{"key":"BFbmt201025_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","volume":"1","author":"J Anderson","year":"1983","unstructured":"Anderson J, Cain K, Gelber R . Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710\u2013719.","journal-title":"J Clin Oncol"},{"key":"BFbmt201025_CR26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life-tables. J Royal Stat Soc B 1972; 34: 187\u2013220.","journal-title":"J Royal Stat Soc B"},{"key":"BFbmt201025_CR27","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","volume":"26","author":"J Lahuerta","year":"2008","unstructured":"Lahuerta J, Mateos M, Mart\u00ednez-Lo\u2032pez J, Rosi\u00f1ol L, Sureda A, de la Rubia J et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775\u20135782.","journal-title":"J Clin Oncol"},{"key":"BFbmt201025_CR28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1182\/blood-2009-03-211953","volume":"114","author":"A Hoering","year":"2009","unstructured":"Hoering A, Crowley J, Shaughnessy Jr JD, Hollmig K, Alsayed Y, Szymonifka J et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009; 114: 1299\u20131305.","journal-title":"Blood"},{"key":"BFbmt201025_CR29","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1200\/JCO.2007.11.7879","volume":"25","author":"D Dingli","year":"2007","unstructured":"Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25: 4933\u20134937.","journal-title":"J Clin Oncol"},{"key":"BFbmt201025_CR30","doi-asserted-by":"crossref","unstructured":"Kumar S, Dingli D, Dispenzieri A, Lacy M, Hayman SR, Buadi F et al. Impact of additional cytoreduction following autologous SCT in multiple myeloma. 2008; 42: 259\u2013264.","DOI":"10.1038\/bmt.2008.166"},{"key":"BFbmt201025_CR31","doi-asserted-by":"crossref","unstructured":"Ladetto M, Pagliano G, Avonto I, Santo L, Ferrero S, Cavallo F et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients. Blood 2007; 110 (Abstract 163).","DOI":"10.1182\/blood.V110.11.530.530"},{"key":"BFbmt201025_CR32","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/sj.leu.2405091","volume":"22","author":"V Arzoumanian","year":"2008","unstructured":"Arzoumanian V, Hoering A, Sawyer J, van Rhee F, Bailey C, Gurley J et al. Suppression of abnormal karyotypes is critical for prolonged survival in myeloma. Leukemia 2008; 22: 850\u2013855.","journal-title":"Leukemia"},{"key":"BFbmt201025_CR33","doi-asserted-by":"crossref","unstructured":"Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Mohty MM et al. Velcade\/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed patients: updated results of the IFM 2005\/01 trial [abstract]. Blood 2007; 110 (Abstract 139).","DOI":"10.1182\/blood.V110.11.450.450"},{"key":"BFbmt201025_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1365-2141.2006.06441.x","volume":"136","author":"M Pineda-Roman","year":"2007","unstructured":"Pineda-Roman M, Bolejack V, Arzoumian V, Anaissie E, van Rhee F, Zangari M et al. Complete response in myeloma extends survival, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393\u2013399.","journal-title":"Br J Haematol"},{"key":"BFbmt201025_CR35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2007-01-067728","volume":"110","author":"F van Rhee","year":"2007","unstructured":"van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827\u2013832.","journal-title":"Blood"},{"issue":"15_suppl","key":"BFbmt201025_CR36","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1200\/jco.2008.26.15_suppl.8504","volume":"26","author":"S. V. Rajkumar","year":"2008","unstructured":"Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams MV et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome with primary therapy and stem cell transplantation. J Clin Oncol 2008; 26 (Abstract 8504).","journal-title":"Journal of Clinical Oncology"},{"key":"BFbmt201025_CR37","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/sj.bmt.1703035","volume":"27","author":"R Alexanian","year":"2001","unstructured":"Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037\u20131043.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201025","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:00:54Z","timestamp":1739887254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,15]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["BFbmt201025"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2010.25","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2010,2,15]]},"assertion":[{"value":"24 July 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}